2022 Agenda

Friday, February 4, 2022

Target Audience

Oncologists, hematologists, pathologists, clinical scientists, nurse practitioners, physician assistants, nurses, and pharmacists charged with the care of the patient with hematologic malignancies

Educational Objectives

Coming Soon!

Time (EST)
9:30 am – 9:40 am

Welcome and meeting overview

John Leonard, MD
Lymphoma Session
9:40 am – 9:55 am

New data in upfront and relapsed aggressive B-cell lymphoma

John Leonard, MD
9:55 am – 10:10 am
What’s new in therapy of indolent and mantle cell lymphoma
Brad Kahl, MD
10:10 am – 10:25 am

Updates in the management of Hodgkin and T-cell lymphomas

Sonali Smith, MD

10:25 am – 10:40 am

Key Conversations: Lymphoma panel discussion and Q&A moderated by Dr. Leonard

Break for Exhibits and Posters (15 minutes)
Multiple Myeloma and CAR T-Cell Therapy Session
10:55 am – 11:10 am
New data in upfront management of multiple myeloma
Sagar Lonial, MD, FACP
11:10 am – 11:25 am
How to integrate novel approached in the treatment of relapsed/refractory myeloma
Kenneth Anderson, MD
11:25 am – 11:40 am

What are the latest approaches for using CAR T-cell therapy for hematologic?

Nina Shah, MD
11:40 am – 11:55 am

Key Conversations: Multiple myeloma panel discussion and Q&A moderated by Dr. Lonial

CLL Session
12:25 pm – 12:40 pm

New therapeutic options in frontline CLL

Susan O’Brien, MD
12:40 pm – 12:55 pm

Updates in management for relapsed and refractory CLL

Jennifer Brown, MD, PhD
12:55 pm – 1:10 pm
Novel agents in CLL
Nitin Jain, MD
1:10 pm – 1:25 pm

Key Conversations: CLL panel discussion and Q&A moderated by Dr. O’Brien

Acute Leukemia Session
1:40 pm – 1:55 pm

What’s new in upfront treatment of AML

Selina Luger, MD
1:55 pm – 2:10 pm

New direction in the treatment of relapsed and refractory AML

Courtney DiNardo, MD
2:10 pm – 2:25 pm

Hot topics in the management of AML

Eunice Wang, MD
2:25 pm – 2:40 pm

Key Conversations: Acute leukemia panel discussion and Q&A moderated by Dr. Luger

MDS/MPN Session
2:55 pm – 3:10 pm
New treatments for MPNs, CML and systemic mastocytosis
Ellen Ritchie, MD
3:10 pm – 3:25 pm
Updates in the management of MDS
Mike Savona, MD
3:25 pm – 3:40 pm

New developments in nonmalignant hematology

Katherine Walsh, MD
3:40 pm – 3:55 pm

Key Conversations: MDS/MPN panel discussion and Q&A moderated by Dr. Ritchie

3:55 pm – 4:00 pm

Closing summary and post session survey

John Leonard, MD